- Home
- RFMZ vs SGHT Comparison
RFMZ vs SGHT Comparison
Compare RFMZ & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFMZ
- SGHT
- Stock Information
- Founded
- RFMZ 2021
- SGHT 2011
- Country
- RFMZ United States
- SGHT United States
- Employees
- RFMZ N/A
- SGHT N/A
- Industry
- RFMZ Trusts Except Educational Religious and Charitable
- SGHT Medical Specialities
- Sector
- RFMZ Finance
- SGHT Health Care
- Exchange
- RFMZ Nasdaq
- SGHT Nasdaq
- Market Cap
- RFMZ 344.8M
- SGHT 304.4M
- IPO Year
- RFMZ N/A
- SGHT 2021
- Fundamental
- Price
- RFMZ $14.22
- SGHT $6.35
- Analyst Decision
- RFMZ
- SGHT Hold
- Analyst Count
- RFMZ 0
- SGHT 8
- Target Price
- RFMZ N/A
- SGHT $6.75
- AVG Volume (30 Days)
- RFMZ 76.6K
- SGHT 157.2K
- Earning Date
- RFMZ 01-01-0001
- SGHT 08-01-2024
- Dividend Yield
- RFMZ 7.43%
- SGHT N/A
- EPS Growth
- RFMZ N/A
- SGHT N/A
- EPS
- RFMZ 0.65
- SGHT N/A
- Revenue
- RFMZ N/A
- SGHT $79,395,000.00
- Revenue This Year
- RFMZ N/A
- SGHT $3.63
- Revenue Next Year
- RFMZ N/A
- SGHT $11.40
- P/E Ratio
- RFMZ $21.49
- SGHT N/A
- Revenue Growth
- RFMZ N/A
- SGHT N/A
- 52 Week Low
- RFMZ $11.28
- SGHT $1.04
- 52 Week High
- RFMZ $14.57
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- RFMZ 49.92
- SGHT 46.39
- Support Level
- RFMZ $14.16
- SGHT $6.12
- Resistance Level
- RFMZ $14.32
- SGHT $7.02
- Average True Range (ATR)
- RFMZ 0.12
- SGHT 0.40
- MACD
- RFMZ -0.00
- SGHT 0.01
- Stochastic Oscillator
- RFMZ 60.61
- SGHT 32.04
About RFMZ RiverNorth Flexible Municipal Income Fund II Inc.
RiverNorth Flex Muni Income Fund II Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.